Research
Hormonal
Adiponectin is an insulin-sensitizing adipokine that improves glucose metabolism by activating AMPK and PPAR-α signaling pathways via AdipoR1 and AdipoR2 receptors, and its levels are inversely correlated with obesity and insulin resistance.
Your fat tissue acts as a hormone factory. In obesity, it produces less of the hormone adiponectin, which normally helps your muscles and liver use insulin. Restoring this signal, either through weight loss or future therapies, can improve insulin sensitivity.
GoodSupportsHIGH confidence
In summary, adiponectin is an abundantly expressed adipokine that exerts a potent insulin-sensitizing effect through binding to its receptors AdipoR1 and AdipoR2, leading to activation of AMPK, PPAR-α, and presumably other yet-unknown signaling pathways. In obesity-linked insulin resistance, both adiponectin and adiponectin receptors are downregulated.
Why this rating
Strong evidence from multiple animal models (knockout/transgenic) and consistent human observational data, though human interventional data is less explicit than mechanistic data.
Source
Adipokines and Insulin Resistance
Katja Rabe et al. · Molecular Medicine · 2008
DOI 10.2119/2008-00058.rabe
narrative_reviewCited 805×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Leptin resistance in obesity is characterized by high circulating leptin levels but a failure of the brain to respond, primarily due to impaired transport across the blood-brain barrier and reduced signaling, leading to continued food intake and insulin resistance.Good
- TNF-α and IL-6 are pro-inflammatory adipokines that contribute to insulin resistance by interfering with insulin signaling pathways, such as through JNK1-mediated serine phosphorylation of IRS-1.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →